Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05886660
Other study ID # NASA 0354 (Aim 1)
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 21, 2022
Est. completion date September 2024

Study information

Verified date May 2024
Source Repurposed Therapeutics, Inc.
Contact Barry Feinberg, MD
Phone 314-697-1330
Email bfeinberg@defenderpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).


Description:

The primary specific aim is to evaluate the use of intranasal scopolamine gel (DPI-386) and sensory augmentation (SA) as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. The proposed sensory augmentation will utilize vibrotactile feedback of pitch and roll tilt using a portable belt (Engineering Acoustics, Inc.). The investigators will utilize exposure to simulated capsule wave motion on a 6DOF platform to provide an operationally relevant platform to induce motion sickness and impair performance on functional tasks. The investigators hypothesize that the combination of intranasal scopolamine gel and sensory augmentation of Earth vertical will be more effective to mitigate motion sickness and improve task performance than when administered separately. Using a randomized double-blind cross-over design, the investigators will compare motion sickness symptom severity and time to endpoint (symptom level defined as severe malaise) in 30 subjects during exposure to simulated wave motion on a 6DOF platform inside of a crew capsule mockup. The investigators will compare four conditions: (1) intranasal scopolamine gel (0.4 mg) with sensory augmentation, (2) intranasal scopolamine gel (0.4 mg) without sensory augmentation, (3) placebo control with sensory augmentation, and (4) placebo control without sensory augmentation. The wave motion stressor will begin 30 min post drug administration and will not exceed 45 min in duration. Performance on a series of functional tasks (dual-task tracking and eye-hand target acquisition) will be performed pre, during, immediately post, and following 15 min of recovery of each test. The bioavailability of scopolamine for each session will be estimated from plasma concentrations obtained at drug administration and then every 15 min up to 2-hr post-dosage. Subjective side effects and performance on the Psychomotor Vigilance Test (PVT) will also be obtained at 15 min intervals. A small pilot study including 10 subjects tested once each will be performed to verify the experimental protocol including that the simulated capsule wave motion will provoke motion sickness symptoms. These pilot sessions will not include the medication nor the blood sampling.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Subjects should be minimally susceptible to provocative motion as evidenced by at least two responses on the Motion Sickness Susceptibility Questionnaire of "Sometimes" or "Frequently." 2. No participants should have neurologic, vestibular or autonomic disorders, or medical conditions that could be worsened by scopolamine (narrow-angle glaucoma or urinary retention 3. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) negative test, confirmed by Food and Drug Administration (FDA) authorized COVID-19 test < 7 days prior to study drug administration or no COVID 19 symptoms up to 10 days prior to study drug administration. Exclusion Criteria: 1. Subjects will be excluded if they are taking other drugs that are capable of causing CNS effects such as antihistamines, tricyclic antidepressants, and muscle relaxants or have hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. 2. Pregnant women are excluded from participation. Women of child-bearing potential will be offered a pregnancy screening test and excluded with a positive test.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DPI-386 Nasal Gel
Subjects will self-administer DPI-386 Nasal Gel.
Placebo Nasal Gel
Subjects will self-administer Placebo Nasal Gel.
DPI-386 Nasal Gel
Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Placebo Nasal Gel
Subjects will self-administer Placebo Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.

Locations

Country Name City State
United States NASA Johnson Space Center Neuroscience Laboratory Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Repurposed Therapeutics, Inc. National Aeronautics and Space Administration (NASA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Motion sickness (MS) symptom severity using Pensacola Diagnostic Index (PDI) scale The PDI scale ranges from 0 to 16 with higher numbers reflecting greater symptom severity (in this study a PDI score of 8 will be used as a motion sickness (MS) endpoint).
During each session, the primary motion sickness symptoms will be recorded every minute during the capsule wave motion stimulation through the MS endpoint (PDI score = 8 points) up to 45 min total.
45 minutes
Secondary Motion sickness symptom severity using a Subjective Discomfort Rating (SDR) The SDR scale ranges from 0-20 with higher numbers reflecting greater symptom severity (20 = vomiting). This will be recorded at the same interval as the PDI score. 45 minutes
Secondary Time to MS endpoint (based on PDI score of 8 points) The time to MS endpoint will be recorded once per session, range of 0-45 with higher numbers reflecting less motion sickness susceptibility. 45 minutes
Secondary Performance measures: response time Response time during eye-hand coordination tasks will be recorded once every 15 min of stimulation (up to three measures per session) with the shorter response representing better performance. 45 minutes
Secondary Performance measures: error Response error during eye -hand coordination tasks will be recorded once every 15 min of stimulation (up to three measures per session), with lower error representing better performance. 45 minutes
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT06128707 - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed NCT05611814 - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms N/A
Recruiting NCT06106256 - Three-Axis Wearable Adaptive Vestibular Stimulator N/A
Completed NCT02839135 - A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Phase 1
Completed NCT04420949 - Sensory Training for Visual Motion Sickness N/A
Completed NCT04184115 - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Phase 3
Completed NCT03988530 - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Phase 3
Terminated NCT04219982 - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Phase 2/Phase 3
Terminated NCT02155309 - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Phase 2/Phase 3
Completed NCT04947423 - Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion Phase 3
Recruiting NCT05903924 - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Recruiting NCT04999449 - Nebulizer Delivery of Intranasal Scopolamine Phase 1
Completed NCT03755596 - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Phase 4
Recruiting NCT05628220 - Motion Sickness Desensitization Using VR N/A
Recruiting NCT06138613 - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Completed NCT04327661 - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Phase 3
Completed NCT06232785 - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients Phase 4
Completed NCT06056622 - Motion Sickness Rehabilitation for Virtual Reality N/A
Withdrawn NCT04331561 - Sensory Training for Orientation and Balance N/A